Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University School of Law
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
    • Comprehensive Support
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Omnibus Outcomes
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Fact Sheets
    • AMR Test Directory
    • Research Compliance
  • News
    • CARB-X News
    • Recommended News
    • In the News
    • Antibiotic Resistance
    • Product Developer News
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University School of Law
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
    • Comprehensive Support
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • 2024 Solicitation
    • Application Process
    • Entering Portfolio
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Fact Sheets
    • AMR Test Directory
  • News
    • CARB-X News
    • Recommended News
    • In the News
    • Antibiotic Resistance
    • Product Developer News
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
GangaGen Biotechnologies

GangaGen Biotechnologies Pvt Ltd, Bangalore, India
http://www.gangagen.com/

KLEBICINS
ENGINEERED ANTIBIOTIC PROTEINS 

Treatment of MDR K. pneumoniae

GangaGen is developing novel antibacterial proteins called klebicins into a narrow-spectrum agent targeting multidrug-resistant K. pneumoniae, including the carbapenem-resistant and ESBL-expressing K. pneumoniae that are of particular clinical concern.  K. pneumoniae presents a serious health challenge around the world and is of increasing concern in low- and middle-income countries (LMICs), where it causes life-threatening infections such as pneumonia and neonatal sepsis. Klebicins’ novel mechanism of action enables specific killing of the target pathogen without impacting the microbiome. This highly innovative project could deliver a first-in-class new therapeutic, and although it is still at an early stage, it has obtained encouraging in vivo efficacy data. The CARB-X award will support further discovery, protein engineering and development of potent klebicins for the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) caused by K. pneumoniae.

Current Development Stage: Pre-Clinical

CARB-X Investment: Initial investment of up to $2.5m, with potential option payments up to $8.1m.

Initial CARB-X Investment Date: August 1, 2020

Carb-X

Led by Boston University

Copyright 2025

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2025

We use cookies to ensure that we give you the best experience on our website. Please visit carb-x.org/legal/ for more information. By clicking “Ok”, you consent to the use of all cookies.OkI do not consent